FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research (IMAGE)

Dana-Farber Cancer Institute

FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research

Caption

Research led at Dana-Farber in Boston by Jennifer Chan, MD, MPH, supports an FDA approval for cabozantinib for previously treated patients with advanced neuroendocrine tumors.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

Kindly credit Dana-Farber Cancer Institute

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.